Dr. Marty Bergman: Addressing Physician Burnout (RWCS)
Dr. Marty Bergman recaps his presentation on physician burnout at the RWCS meeting in Maui.
Lancet reports that, based on a literature review and metanalysis, patients and surgeons can expect a hip replacement to last 25 years in around 58% of patients.
In the USA, there is an estimated 400,000 total hip arthroplasties (THA) annually. UK invesigators set out to answer the question: how long does a hip replacement last?
Dr. John Cush RheumNow
7 years 8 months ago
More than half (53%) of hospital deaths are from sepsis and sepsis is the most common immediate cause of death (35%) according to a medical record review from 6 academic centers https://t.co/Sp5rFTbg3m
Dr. John Cush RheumNow
7 years 8 months ago
"In order to solve a problem, you need to sell it first.....remarket your problem with a story that resonates." - Seth Godin https://t.co/HHF9eMV7sk
Dr. John Cush RheumNow
7 years 8 months ago
Dr Orrin Troum shows data on ANA negative pts. Should this include those with cytoplasmic staining? #RWCS2019 https://t.co/EDV882CQ9E
Dr. John Cush RheumNow
7 years 8 months ago
Dr Orrin Troum shows that TB Tspot is more sensitive than QFT in school of TB. But no specificity data. #RWCS2019 https://t.co/KJ2i0EKim3
Dr. John Cush RheumNow
7 years 8 months ago
The RheumNow Weekly Podcast is up! Info on SEAM-PsA, SEAM trial, MRI T2T, biologics & infection, contraceptive use, ANA negative lupus. View here>> https://t.co/tv2ANE0LAp or listen on iTunes or SoundClound https://t.co/uXZEI1jmkJ
Dr. John Cush RheumNow
7 years 8 months ago
Dr Anne Stevens. Other arc options for localized scleroderma include tocilizumab and abatacept. #RWCS2019 https://t.co/AIfARTZ3CD
Dr. John Cush RheumNow
7 years 8 months ago
Dr Anne Stevens shows that CARRA pediatric rheums treat localized scleroderma with steroids and MTX #RWCS2019 https://t.co/h9s5Owz8J3
Dr. John Cush RheumNow
7 years 8 months ago
Dr Anne Stevens compare localized and diffuse pediatric scleroderma #RWCS2019 https://t.co/KJLGHlvqiE
Dr. John Cush RheumNow
7 years 8 months ago
FREEDOM trial 3,591 postmenop. women Rx w/ denosumab vs PBO x3 years - No difference in dental procedures (~45%), adjudicated osteonecrosis of jaw (13 cases) - risk was 0.68% vs. 0.05% w/ and withour invasive oral procedures. https://t.co/dxWuzEjUnk
Dr. John Cush RheumNow
7 years 8 months ago
Dr Eric Ruderman shows that filgotinib (Jak inhibitor) maybe effect in ankylosing spondylitis. #RWCS2019 https://t.co/0km5vMHFpQ
Dr. John Cush RheumNow
7 years 8 months ago
Dr Eric Ruderman shows data on the lack of effect with ustrkinumab in biological naive ankylosing spondylitis. #RWCS2019 https://t.co/Wqx7Us1Qrl
Dr. John Cush RheumNow
7 years 8 months ago
Dr Mark Genovese on Filgotinib (jak 1 inhibitor in development) showing no diff in responses despite falling 1, 2, 3 biologics #RWCS2019 https://t.co/dk7orkumEd
